Hair Growth Treatment

Nektar Reports Phase 2b Proof-of-Concept for Rezpegaldesleukin in Severe Alopecia Areata

December 17, 2025 /

Nektar Therapeutics has announced topline results from its Phase 2b REZOLVE-AA trial evaluating rezpegaldesleukin (REZPEG) in patients with severe-to-very-severe alopecia areata (AA). The data establish clinical proof of concept and support advancement into Phase 3 development, positioning rezpegaldesleukin as a potential non-JAK option for this autoimmune hair-loss condition. What is Rezpegaldesleukin? Rezpegaldesleukin is a first-in-class…

Best Minoxidil for Men: Our Top 5 Brands of 2026

December 16, 2025 /

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Minoxidil is a clinically proven hair-regrowth agent that is one of only two FDA-approved treatments for pattern hair loss. It has consistently yielded favorable outcomes for millions of men worldwide, and its effectiveness is supported by decades of study…

Best Minoxidil for Women: Top 4 Products of 2026

December 16, 2025 /

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Today’s market is saturated with hair-loss products for women, and navigating advertising claims to find effective treatments can be challenging. Top products demonstrate proven efficacy and safety with customization features and affordability to suit a range of female hair-restoration…

Topical Dutasteride Before and After: Ultimate Guide

November 12, 2025 /

Commissions we earn from partner links on this page do not affect our opinions or evaluations. In recent years, topical dutasteride has captured increasing attention among people seeking alternatives to standard oral therapies, often due to intolerance or limited results. This surge is fueled by social media testimonials and before-and-after photos that highlight dramatic transformations.…

GeneSkin: A Potential mRNA Therapy for Skin and Hair Rejuvenation

October 6, 2025 /

A new contender in the dermatology field is GeneSkin, an mRNA-based platform developed at Harvard’s Wyss Institute, which aims to address some of the unmet needs in skin and hair health.  The minds behind GeneSkin include geneticist George Church and his team, who have been studying which genes help skin and hair stay healthy. By…

Ulo Debuts as the Latest Entrant in the Telehealth Hair Care Industry

June 25, 2025 /

Commissions we earn from partner links on this page do not affect our opinions or evaluations. This isn’t news about future treatments. Instead, this is about a new U.S.-based telehealth brand, Ulo, and its innovative prescription and over-the-counter treatments for hair growth. There are dozens of telehealth hair care brands, yet Follicle Thought has never…

HCW Biologics Receive FDA Clearance For Alopecia Areata Trial

February 4, 2025 /

HCW Biologics has received FDA clearance to start a first-in-human safety trial for their potential alopecia areata treatment, HCW9302.  Who Are HCW Biologics? HCW Biologics Inc. is a clinical-stage biopharmaceutical company based in Miramar, Florida. The company focuses on developing immunotherapies targeting chronic inflammation in age-related diseases like cancer, autoimmune disorders, and neurodegenerative conditions. The…

Sun Pharma Reveals Efficacy Data for Deuruxolitinib for Alopecia Areata

October 28, 2024 /

Sun Pharma revealed data at the 2024 Fall Clinical Dermatology Conference (held between October 24th – 27th, 2024, in Las Vegas, Nevada) regarding the efficacy of LEQSELVI (deuruxolitinib), its treatment for alopecia areata (AA). The data includes collated results from open-label extension studies that have monitored LEQSELVI used for up to 68 weeks. Improvements were…

Kintor Announces Enrollment for New Trial and Update of Previous Phase 3 for Androgenic Alopecia

October 21, 2024 /

Kintor Pharmaceutical has recently announced the enrollment of its first participant in its “Pivotal Clinical Trial”. This is a Phase 2/3 trial in which men with androgenic alopecia will be treated with either vehicle control, 0.5%,  or 1% topical for 24 weeks. The trial will be conducted in China, with 222 patients enrolled in each…

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.